SVF
Level C· Early Human ResearchProspective Study

Platelet-like cells differentiated from adipose-derived mesenchymal stem cells inhibit acute inflammation of tendinopathy in rats.

Torii A., Yamada Y., Ono-Uruga Y., Sato Y., Kaneko Y., Nakamura S.

Prospective Study on Tendon Injury, Chronic Inflammation, published in J Bone Miner Metab (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Bone Miner Metab (2026)
Country
Japan
Reported sample size
—
PMID
41042331
DOI
10.1007/s00774-025-01647-2

Abstract (original English)

Tendinopathy, a disease that causes inflammation and pain and limits patients' activities of daily living, is considered particularly important to treat during the acute inflammatory phase to prevent the transition to chronic degeneration. Recently, platelet-rich plasma (PRP) has been used to treat tendinopathy; however, it is not clear whether platelets themselves, which are the active component of PRP, could be effective in treating tendinopathy. We made rat Achilles tendinopathy models by incision of the calcaneal attachment and administrated platelet-like cells derived from adipose-derived mesenchymal stem cells (ASCL-PLCs) to the injury site and investigated the anti-inflammatory effect. ASCL-PLCs significantly inhibits the inflammatory cytokine expression and inflammatory cell infiltration in acute tendonitis in a rat Achilles tendon injury model in vivo. Interestingly, we observed no xeno-reaction when human-derived ASCL-PLCs were administered to wild-type rats in vivo. Moreover, IL-6 expression and phosphorylation seen in NIH3T3 fibroblasts treated with IL-6 plus soluble IL-6 receptor were both significantly suppressed by ASCL-PLCs in vitro. ASCL-PLC has advantages over existing PRP therapies, including the ability to be cryopreserved after quality checks, and homogeneous populations of ASCL-PLCs can be prepared in large quantity. We conclude that in the future ASCL-PLC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
AnimalsTendinopathyMesenchymal Stem CellsCell DifferentiationRatsAdipose TissueInflammationMiceHumansNIH 3T3 Cells
Ankle & FootTendon InjuryChronic Inflammation
View on PubMedDOI

Related research